Stockscreener 앱 받기
87.13
0.61%
0.53
전일 마감가:
$86.60
열려 있는:
$86.66
하루 거래량:
610.26K
Relative Volume:
0.15
시가총액:
$50.22B
수익:
$6.30B
순이익/손실:
$1.07B
주가수익비율:
47.34
EPS:
1.8406
순현금흐름:
$1.09B
1주 성능:
+0.86%
1개월 성능:
-1.28%
6개월 성능:
+7.58%
1년 성능:
+16.73%
1일 변동 폭
$86.55
$87.73
1주일 범위
$84.83
$88.41
52주 변동 폭
$72.42
$96.29
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
87.13 | 50.22B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
103.79 | 179.60B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.78 | 118.68B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
296.35 | 113.67B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.32 | 64.23B | 20.62B | 3.56B | 3.48B | 2.3847 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | Barclays | Overweight |
| 2026-07-28 | 개시 | UBS | Buy |
| 2026-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2026-04-01 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-10-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death - Benzinga
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corporation $EW Stock Sold by Ninety One UK Ltd - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One North America Inc. - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Earnings Preview: What to Expect - Yahoo Finance
Edwards Lifesciences Earnings Preview: What to Expect - Barchart.com
Edwards Lifesciences Earnings Preview: What to Expect - inkl
Edwards Lifesciences Corporation (EW) Options ChainYahoo Finance - Yahoo! Finance Canada
Edwards Lifesciences Corporation (EW) Options Chain - Yahoo! Finance Canada
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock - Investing.com
Edwards Lifesciences Corp (EW) Insider Daniel Lippis Sells 619 S - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Is Edwards Lifesciences (NYSE:EW) Entering A Stronger Phase? - Kalkine Media
Why Edwards Lifesciences (EW) Stock Is Falling Today - Quiver Quantitative
UBS reiterates Edwards Lifesciences stock rating on endpoint expectations - Investing.com
Edwards Lifesciences (EW) Stock Forecast and Price Target 2026 $EW - MarketBeat
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise? - Zacks Investment Research
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - BioSpace
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - Yahoo Finance
Edwards Lifesciences Corp (CEUX:EWLd) Stock Earnings Transcripts - GuruFocus
Edwards Lifesciences (NYSE:EW) Share Price Breaks Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
What Does Expanded TAVR Coverage Mean for Edwards Lifesciences (NYSE:EW)? - Kalkine Media
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating - Yahoo Finance
Edwards Lifesciences to Host Investor Event in Conjunction With TCT - Yahoo Finance
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve - Benzinga
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating - marketscreener.com
Edwards Lifesciences (NYSE:EW) Stock Forecast & Analyst Predictions - Simply Wall Street
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients - BioSpace
Edwards Lifesciences wins FDA approval for AUTUS - Mugglehead Investment Magazine
Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adj - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Receives FDA Approval For AUTUS Size-Adjustable Valve - marketscreener.com
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Edwards Lifesciences Corporation Stocks - tradingview.com
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Claim your share of the $39 million Edwards Lifesciences securities class action settlement - Claim Depot
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class ActionEW - TMX Newsfile
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions - Yahoo Finance
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
에드워즈라이프사이언시스 주식 (EW) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | CVP, TAVR |
Oct 08 '26 |
Sale |
85.65 |
619 |
53,017 |
40,034 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Option Exercise |
72.68 |
619 |
44,989 |
40,653 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Sale |
87.51 |
619 |
54,169 |
40,034 |
| Dahl Andrew M. | SVP, Corporate Controller |
Aug 31 '26 |
Sale |
91.06 |
544 |
49,534 |
14,868 |
| Dahl Andrew M. | Officer |
Aug 31 '26 |
Proposed Sale |
91.06 |
544 |
49,534 |
0 |
| Bruls Annette | CVP, EMEACLA |
Aug 28 '26 |
Sale |
89.98 |
2,644 |
237,907 |
17,984 |
| Bruls Annette | Officer |
Aug 28 '26 |
Proposed Sale |
89.98 |
2,644 |
237,907 |
0 |
| Markowitz Wayne | CVP, JAPAC |
Aug 26 '26 |
Sale |
91.47 |
1,240 |
113,417 |
20,294 |
| Markowitz Wayne | Officer |
Aug 26 '26 |
Proposed Sale |
91.47 |
1,240 |
113,417 |
0 |
| Chopra Daveen | Officer |
Aug 26 '26 |
Proposed Sale |
91.02 |
31,800 |
2,894,440 |
0 |
0.01%
자본화:
|
볼륨(24시간):